Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Tirzepatide trims risk of major adverse cardiovascular events
Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.
Tirzepatide trims risk of major adverse cardiovascular events
26 Nov 2025
Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD
The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.
Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD
25 Nov 2025
Semaglutide lowers kidney fat, improves glomerular haemodynamic in T2D patients with CKD
Treatment with semaglutide helps reduce kidney fat and enhance glomerular haemodynamic in adult patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the REMODEL trial.
